Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 844

1.

Surviving the blockbuster syndrome.

Service RF.

Science. 2004 Mar 19;303(5665):1796-9. No abstract available.

PMID:
15031490
2.

Financial interests constrain drug development.

Garattini S.

Science. 1997 Jan 17;275(5298):287. No abstract available.

3.

Drug discovery.

Kennedy D.

Science. 2004 Mar 19;303(5665):1729. No abstract available.

4.

[Discount for only one drug of the same group leads to impaired health care quality].

Bergström R.

Lakartidningen. 2006 Feb 8-14;103(6):387-8; discussion 388. Swedish. No abstract available.

PMID:
16536044
5.

Protect pharmaceutical innovation.

Musselwhite LW, Andrews J.

Science. 2010 Jun 11;328(5984):1354; author reply 1354-5. doi: 10.1126/science.328.5984.1354-a. No abstract available. Erratum in: Science. 2010 Nov 19;330(6007):1047.

PMID:
20538934
6.

[Research projects of pharmaceutical companies].

Okuyama S.

Nihon Yakurigaku Zasshi. 2008 Aug;132(2):77-8. Japanese. No abstract available.

PMID:
18792463
7.

Intellectual property. Fixing the legal framework for pharmaceutical research.

Knowles SM.

Science. 2010 Feb 26;327(5969):1083-4. doi: 10.1126/science.1184188. Epub 2010 Feb 11. No abstract available.

PMID:
20150445
8.

In search of sustainability: process R&D in light of current pharmaceutical industry challenges.

Federsel HJ.

Drug Discov Today. 2006 Nov;11(21-22):966-74. Epub 2006 Sep 26. Review.

PMID:
17055405
9.

Do drug prices reflect development time and government investment?

Keyhani S, Diener-West M, Powe N.

Med Care. 2005 Aug;43(8):753-62.

PMID:
16034288
10.

Sending pharma better signals.

Avorn J.

Science. 2005 Jul 29;309(5735):669. No abstract available.

11.

Productivity counts--but the definition is key.

Mervis J.

Science. 2005 Jul 29;309(5735):726. No abstract available.

PMID:
16051784
12.

Drug costs threaten patent protection.

Cimons M.

Nat Med. 2003 Jan;9(1):9. No abstract available.

PMID:
12514706
13.

When Pharma merges, R&D is the dowry.

Agnew B.

Science. 2000 Mar 17;287(5460):1952-3. No abstract available.

PMID:
10755948
14.

Are we living in the end of the blockbuster drug era?

Debnath B, Al-Mawsawi LQ, Neamati N.

Drug News Perspect. 2010 Dec;23(10):670-84. doi: 10.1358/dnp.2010.23.10.1506088. Review.

PMID:
21180653
15.

IP litigation in China could drive innovation.

Jia H.

Nat Biotechnol. 2004 Apr;22(4):368. No abstract available.

PMID:
15060539
16.

Orphan drugs of the future?

Service RF.

Science. 2004 Mar 19;303(5665):1798. No abstract available.

PMID:
15031491
17.

[Competition and prices in the Mexican pharmaceutical market].

Molina-Salazar RE, González-Marín E, Carbajal-de Nova C.

Salud Publica Mex. 2008;50 Suppl 4:S496-503. Review. Spanish.

18.

The hunt for a new drug: five views from the inside.

Mervis J.

Science. 2005 Jul 29;309(5735):722. No abstract available.

PMID:
16051781
19.

The brains behind blockbusters.

Couzin J.

Science. 2005 Jul 29;309(5735):728. No abstract available.

PMID:
16051786
20.

Cutting the cost of drug development?

Rawlins MD.

Nat Rev Drug Discov. 2004 Apr;3(4):360-4. Review. No abstract available.

PMID:
15060531

Supplemental Content

Support Center